Special Issue

Pathology, Diagnosis and Treatment in Non-small Cell Lung Cancer

Message from the Guest Editor

Lung cancer is the leading cause of cancer death worldwide. Over the past decade, significant improvements in overall survival were observed in patients with non-small cell lung cancer. A backbone for improving prognosis are advanced diagnostic and treatment techniques. Today, non-small lung cancer is a heterogenous disease. Critical to the management of this cancer is a proper pathological diagnosis, including the phenotyping of tumor cells. All patients with nonsquamous NSCLC should have the results of testing for potentially targetable mutations before therapy for advanced lung cancer is implemented. Approximately 30-50% of patients with lung cancer tumors have potentially curable driver alterations. A group of patients without a driven mutation can be treated with immunotherapy. PDL1 expression has many limitations as a biomarker. The establishment of a well-defined universal predictive biomarker for immunotherapy is an unmet need. This Special Issue aims to review the advances in pathology, molecular diagnosis and treatment techniques in non-small cell lung cancer.

Guest Editor

Dr. Adam Płużański

Lung Cancer and Chest Tumors Department, Maria Sklodowska-Curie National Research Institute of Oncology, 02-781 Warsaw, Poland

Deadline for manuscript submissions

closed (17 February 2025)

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:
free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:
indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:
JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)